Why Alzheimer’s May Be Biopharma’s Most Challenging Target
By Don Seiffert
George Vradenburg likens the encroaching Alzheimer’s epidemic to AIDS in the 1990s, except with victims who can’t speak up for themselves, and caregivers who are just too exhausted.
As co-founder and president of UsAgainst Alzheimer’s, a non-profit whose ambitious mission is to stop the fatal disease by 2020, Vradenburg has an uphill climb in the next seven years. Maybe that’s why in a panel session Wednesday at the Drug Information Association’s annual meeting in Boston titled, “Advancing Alzheimer’s Innovation: A Call to Action,” he went so far as to say that he believes most of the public is “murderously indifferent” to those suffering from the disease.
It’s a harsh indictment - especially to a crowd of scientists and biotech executives gathered to focus on the progress that’s been made in the past year in drug development. But it’s also one which I’ve come to believe is largely right.
Read the full piece here.